Bristol-Myers Squibb’s $4.1 Billion Sale of ConvaTec

Bristol-Myers Squibb Company has signed a definitive agreement to sell its ConvaTec business unit to Nordic Capital Fund VII and Avista Capital Partners for approximately $4.1 billion. ConvaTec is a world leader in the development and marketing of innovative wound therapeutics and ostomy care products. Cravath is representing Bristol-Myers Squibb in this transaction. The lawyers involved in the matter were partners Susan Webster and Thomas E. Dunn and associates Mile T. Kurta, Leam Nelson, Jane A. Okpala and Justin S. Tichauer on corporate matters; associate Joyce Law on real estate matters; partner C. Allen Parker and associate Christopher J. Kelly on banking matters; partners Stephen L. Gordon and Lauren Angelilli and associates Luke A. Facer and Sonia Rodriguez Garcia on tax matters; partner Jeffrey A. Smith and associate Annmarie M. Terraciano on environmental matters; and partner Elizabeth L. Grayer and associates Robin C. Landis and Jeremy N. Sheff on antitrust matters. The deal was announced on May 2, 2008.